A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

Astellas Pharma Inc29 enrolled

Overview

A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.

A phase II, multicenter, open-label study in subjects with unresectable Stage III or metastatic (Stage IV) Melanoma to evaluate the efficacy and safety of YM155

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Melanoma

Interventions

YM155DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically or cytologically confirmed unresectable stage III or IV malignant melanoma * Life expectancy \>12 weeks Exclusion Criteria: * History of other malignancy in the last 5 years * Major surgery within the past 21 days

Locations (9)

Unnamed facility

Tuscon, Arizona, United States

Unnamed facility

Little Rock, Arkansas, United States

Unnamed facility

Aurora, Colorado, United States

Unnamed facility

Washington D.C., District of Columbia, United States

Outcomes

Primary Outcomes

Tumor response rate

Time frame: 6 cycles

Secondary Outcomes

Duration of response

Time frame: 6 cycles

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.